Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: Does anything work?

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 78-86

  Kundranda, Madappa N ^a   Tibes, Raoul ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute myelogenous leukemia; Acute myeloid leukemia; AML; Blast phase; Essential thrombocythemia; JAK2 inhibitors; Leukemic transformation; Myeloproliferative neoplasm; Pathogenesis; Polycythemia vera; Primary myelofibrosis; Treatment

Indexed keywords

ALKYLATING AGENT; ANDROGEN; ANTHRACYCLINE; ANTIANEMIC AGENT; AZACITIDINE; BCR ABL PROTEIN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; MELPHALAN; MITOXANTRONE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PHOSPHORUS 32; PIPOBROMAN; RUXOLITINIB; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER SURVIVAL; CHRONICITY; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; SPLENECTOMY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; BLAST CELL CRISIS; DISEASE COURSE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS;

EID: 84859238493     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0107-9     Document Type: Article

References (74)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (who) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951. This key reference addresses the current diagnostic WHO criteria changes for the diagnosis of MPNs.
2. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-5.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of thetyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61. (Pubitemid 40386783)
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8. (Pubitemid 40663494)
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-90. (Pubitemid 40570926)
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97. (Pubitemid 40544655)
7. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis(PMF), post polycythemia vera myelofibrosis (POST-PV MF), post essential thrombocythemia myelofibrosis (POST-ET MF), blast phase pmf (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia Res. 2007;31:737-40. (Pubitemid 46855906)
8. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experien ce with 91 cases. Blood. 2005;105:973-7. (Pubitemid 40170863)
9. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664-70. (Pubitemid 40446255)
10. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29:573-82.
11. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653-5. (Pubitemid 34579157)
12. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931-40.
13. Mesa RA, Powell H, Lasho T, et al. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Res. 2006;30:1457-60. (Pubitemid 44307317)
14. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F alleleburden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756-61. (Pubitemid 351559282)
15. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disordersare frequently negative for the JAK2-V617F mutation. Blood.2007;110:375-9. (Pubitemid 47026857)
16. Swierczek SI, Yoon D, Prchal JT. Blast transformation in a patientwith primary myelofibrosis initiated from JAK2 V617F progenitor. Blood. 2007;110:a4665.
17. Tam CS, Nussenzveig RM, Popat U, et al. The natural history andtreatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood. 2008;112:1628-37.
18. Lopes da Silva R, Ribeiro P, Lourenco A, et al. What is the role ofJAK2V617F mutation in leukemic transformation of myeloproliferative neoplasms? Lab Hematol. 2011;17:12-6.
19. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891-900.
20. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115:2003-7.
21. Kralovics R. Genetic complexity of myeloproliferative neoplasms Leukemia. 2008;22:1841-8.
22. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-68. (Pubitemid 46193073)
23. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686-9. (Pubitemid 351213460)
24. Pancrazzi A, Guglielmelli P, Ponziani V, et al. A sensitive detection method for MPLW515l or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008;10:435-41.
25. Pikman Y, Lee BH, Mercher T, et al. MPLW515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
26. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930-5.
27. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905-11.
28. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183-6.
29. Boultwood J, Perry J, Zaman R, et al. High-density single nucleotidepolymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010;24:1139-45.
30. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB,TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198-206.
31. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011
32. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-44.
33. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339-44.
34. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies inblast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24:1713-8.
35. Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor IKAROS in myeloproliferative neoplasms. Leukemia. 2010;24:1290-8.
36. Osgood EE. Contrasting incidence of acute monocytic and granulocyticleukemias in p32-treated patients with polycythemia vera and chronic lymphocytic leukemia. J Lab Clin Med. 1964;64:560-73.
37. Parmentier C. Use and risks of phosphorus-32 in the treatment of polycythaemia vera. Eur J Nucl Med Mol Imaging. 2003;30:1413-7. (Pubitemid 37247961)
38. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol.2002;116:576-81. (Pubitemid 34178656)
39. Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417-21.
40. Najean Y, Rain JD. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of65 years. Blood. 1997;90:3370-7. (Pubitemid 27473405)
41. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-51. (Pubitemid 37430269)
42. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112:2726-32. (Pubitemid 351969217)
43. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian cooperative study group on myeloid with myeloid metaplasia. Blood. 1998;91:3630-6. (Pubitemid 28225729)
44. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361-70. (Pubitemid 44036566)
45. Wang JC, Chen W, Nallusamy S, et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116:582-6. (Pubitemid 34178657)
46. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735-3742. This is firsttherapy paper that demonstrates success using azacitidine in treating patients with MPNs that had transformed to AML.
47. Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol. 2006;19:519-33. (Pubitemid 43869475)
48. Scott BL, Storer BE, Greene JE, et al.Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007;13:345-54.
49. Ramakrishnan A, Sandmaier BM. Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Rev Hematol. 2010;3:23-33.
50. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27:4563-9.
51. Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood. 2000;96:4007.
52. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy inmyelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-64. (Pubitemid 44232010)
53. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29:504-15.
54. Eghtedar A, Verstovsek S, Cortes JE, et al. Phase II study of the JAK2 inhibitor, INCB018424, in patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (SAML) (Abstract 509). Blood 2010.
55. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor VISMODEGIB (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502-11.
56. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of thehedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164-72.
57. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26:5198-203.
58. Tibes R, McDonagh KT, Lekakis L, et al. Phase I study of the novel survivin and CDC2/CDK1 inhibitor terameprocol in patients with advanced leukemias. Blood 2009; ASH Annual Meeting Abstract #1039.
59. Vannucchi AM, Guglielmelli P, Lupo L, et al. A phase 1/2 study ofRAD001, an mTOR inhibitor, in patients with myelofibrosis: Final results. ASH Annual Meeting Abstracts. 2010;116:314.
60. Mascarenhas J, Wang X, Rodriguez A, et al. A phase I study ofLBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET MF). ASH Annual Meeting Abstracts. 2009;114:308.
61. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2a study of the histone-deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Blood. 2008;112:100.
62. Saberwal G, Horvath E, Hu L, et al. The interferon consensussequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem. 2009;284:33242-54.
63. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon alfa-2a induces complete hematologic and molecular responses withlow toxicity in polycythemia vera. Blood. 2008;112:3065-72.
64. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418-24.
65. Konieczna I, Horvath E, Wang H, et al. Constitutive activation of Shp2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest. 2008;118:853-67. (Pubitemid 351364594)
66. Invernizzi R, Travaglino E, Benatti C, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol. 2006;76:494-501.
67. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24:1302-9.
68. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N EnglJ Med. 2010;362:369-70.
69. Ding Y, Harada Y, Imagawa J, et al. AML1/RUNX1 point mutationpossibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114:5201-5.
70. Verstovsek S, Kantarjian H, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-27.
71. Verstovsek S, Passamonti F, et al. Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera(PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood. 2010;116(21):313. ASH Annual Meeting Abstracts.
72. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-96.
73. Verstovsek S, Deeg HJ, et al. Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis. Blood. 2010;116(21):3082. ASH Annual Meeting Abstracts.
74. Moliterno AR, Roboz GJ, et al. An Open-Label Study of CEP-701in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis. Blood. 2008;112(11):99. ASH Annual Meeting Abstracts.